Lates News

Lai plans to make India the center of its global supply chain as part of its earlier commitment to invest $1 billion in India for contract manufacturing. After the successful launch of its flagship weight loss drug Mounjaro in South Asian countries, which saw sales double in just a few months, the company currently does not have its own manufacturing facility in India. It plans to utilize India's strong contract manufacturing system to export its drugs produced in India to markets around the world as part of its broader supply network. The company also plans to introduce more products to India.